Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Smallpox vaccine provides more protection than previously thought

26.05.2003


Researchers at Oregon Health & Science University this week announced preliminary study results showing smallpox vaccine protection lasts longer than previously thought. Until now, it was widely accepted that smallpox vaccine protection lasted approximately three to five years. However, early study data shows that significant, partial protection may last many decades after inoculation.



“More than 90 percent of Americans older than 35 have already been vaccinated against smallpox. This translates into about 150 million people who are likely to have at least some level of detectable immunity against this disease,” said Mark Slifka, Ph.D., a researcher at the OHSU Vaccine and Gene Therapy Institute. Slifka and his colleague Erika Hammarlund presented the initial findings at this week’s meeting of the American Society for Microbiology in Washington, D.C.

To conduct their research, Slifka and his colleagues studied blood samples taken from 306 people who had received smallpox vaccinations. These immunizations occurred as recently as one month prior to testing and as long ago as 75 years. Scientists concentrated on two types of immunity in these patients. The first form of immunity is linked to levels of antibody produced in the body in response to the vaccine. These antibodies protect patients by forming the first line of defense against smallpox if an exposure occurs. The second form of immunity is T-cells programmed by the vaccine to attack the smallpox virus.


“What we found was that while T-cell immunity declines slowly over time, antibody immunity can last throughout a person’s life,” said Slifka. “Remarkably, we were able to identify some types of virus-specific immunity in volunteers who were vaccinated up to 75 years ago, indicating that their immune systems remembered the virus for three-fourths of a century after smallpox vaccination. These results are likely to have a profound impact on current models and theories on how rapidly smallpox would spread in contemporary populations because immunity following smallpox vaccination is lasting much longer than people expected.”

However, Slifka believes the pre-event vaccination of first-responders, the military, or members of smallpox task force teams remains necessary. “People with a potential occupational risk for exposure to smallpox should still be vaccinated as a safety precaution” he said. “Likewise, in the event of a smallpox outbreak, those who have come into contact with smallpox victims should be vaccinated or revaccinated as a fundamental safeguard against contracting the disease, and this serves as an important measure against spreading smallpox to others.”

Another important finding of the study was that people who had received vaccinations several times in the past had essentially the same immunity level as those vaccinated once or twice. Researchers believe immunizations create a short-term burst of higher immunity that, over time, appears to return to a set point no matter how many times a person has been vaccinated.

The smallpox vaccine’s active ingredient is a virus called vaccinia, that is closely related to smallpox. However, unlike smallpox, vaccinia does not cause serious health problems in most patients. The virus promotes smallpox protection by causing the body to produce protective antibodies and white blood cells that can search for and destroy smallpox-infected cells.

Future studies in the Slifka lab will focus on determining the level of immunity that could be considered protective in the case of an outbreak. This information would help health officials determine which members of the previously vaccinated population are at highest risk. It would also guide emergency health providers in making decisions about vaccination priorities.

“This research helps illustrate how world events have refocused scientific research and resources to better respond to major health threats that could have devastating effects,” added Jay Nelson, Ph.D., director of the Vaccine and Gene Therapy Institute. “OHSU has proposed a number of initiatives to aid in this national effort.”

Slifka and many of his colleagues are part of the newly formed Pacific Rim Biodefense Center (PRBC). The PRBC is a collaborative effort headed by OHSU. Member institutions will investigate new ways to fight infectious diseases – spread through natural causes or bioterrorism – that threaten human health. The PRBC includes the University of Hawaii at Manoa; the University of Nevada, Reno; Oregon State University; the University of Idaho; Princeton University; and Pacific Northwest National Laboratory (PNNL).

In addition to the PRBC, OHSU has proposed expansion of research and facilities aimed at developing vaccines to combat infectious disease. More information about this effort, called the Pacific Rim Vaccine Initiative, can be found at www.ohsu.edu/prvi.

Jim Newman | EurekAlert!
Further information:
http://www.ohsu.edu/
http://www.ohsu.edu/prvi

More articles from Health and Medicine:

nachricht Researchers show p300 protein may suppress leukemia in MDS patients
28.03.2017 | University of Miami Miller School of Medicine

nachricht When writing interferes with hearing
28.03.2017 | Université de Genève

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers create artificial materials atom-by-atom

28.03.2017 | Physics and Astronomy

Researchers show p300 protein may suppress leukemia in MDS patients

28.03.2017 | Health and Medicine

Asian dust providing key nutrients for California's giant sequoias

28.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>